Stephen Ma has served as the Company’s Chief Accounting Officer since November 2022 and previously served as its Vice President of Finance from January 2022 to November 2022.
Mr. Ma has more than 15 years of finance and operational expertise across pharmaceuticals and venture backed biotechnology companies. He most recently served as Director of Finance and Operations for Anwita Biosciences, Inc., a clinical stage company, from August 2019 to January 2022.
Prior to that, from May 2016 to August 2019, he served as Sr. Director of Finance and Controller for Semnur Pharmaceuticals, a specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients,which was acquired by the Company in March 2019.
Prior to that, he served as Controller for Globavir and part of the management team that worked on its IPO process. He also served as the Controller for Ardelyx, which went public in 2014. Prior to that, Mr. Ma served in various finance positions at PDL BioPharma and Hyperion Therapeutics.
Mr. Ma began his career with more than 10 years in high technology companies and has a wealth of experience in finance, strategic planning, commercial launching, debt financing, public offerings and M&A transactions. Mr. Ma holds a B.S. in Finance and M.A. in Economics from San Jose State University.
What is Stephen Hoi Ma's net worth?
The estimated net worth of Stephen Hoi Ma is at least $3.22 thousand as of October 16th, 2024. Mr. Ma owns 652 shares of Scilex stock worth more than $3,221 as of September 25th. This net worth estimate does not reflect any other investments that Mr. Ma may own. Learn More about Stephen Hoi Ma's net worth.
How do I contact Stephen Hoi Ma?
Has Stephen Hoi Ma been buying or selling shares of Scilex?
Stephen Hoi Ma has not been actively trading shares of Scilex in the last ninety days. Most recently, on Wednesday, October 16th, Stephen Hoi Ma bought 191 shares of Scilex stock. The stock was acquired at an average cost of $33.95 per share, with a total value of $6,484.45. Following the completion of the transaction, the chief financial officer now directly owns 652 shares of the company's stock, valued at $22,135.40. Learn More on Stephen Hoi Ma's trading history.
Who are Scilex's active insiders?
